Risultati per: Gestione dei pazienti con angina stabile

Circulation, Volume 150, Issue 1, Page e5-e6, July 2, 2024.

Circulation, Volume 150, Issue 1, Page e3-e4, July 2, 2024.

Il decreto garantisce che ogni prestazione sia assicurata nei tempi previsti dalle prioirità indicate in ricetta. Ma ci sono anche doveri per i cittadini

Andos, ‘È un fenomeno che assume rilevanza crescente’

In 80 centri italiani. ‘Non si parla più solo di sopravvivenza’

Schillaci, ‘Dichiara il tuo Sì in comune. Donare è una scelta di vita’. Al via campagna negli Uffici anagrafe

Giornata nazionale donazione organi,’Dichiara tuo Sì in comune’

‘Spesso sono forme lievi non diagnosticate in età infantile’

Aifa approva la rimborsabilità della nuova formulazione in compresse di un farmaco mirato

Introduction
Chronic stable angina is common and disabling. Cardiac rehabilitation is routinely offered to people following myocardial infarction or revascularisation procedures and has the potential to help people with chronic stable angina. However, there is insufficient evidence of effectiveness and cost-effectiveness for its routine use in this patient group. The objectives of this study are to compare the effectiveness and cost-effectiveness of the ‘Activate Your Heart’ cardiac rehabilitation programme for people with chronic stable angina compared with usual care.

Methods and analysis
ACTIVATE is a multicentre, parallel-group, two-arm, superiority, pragmatic randomised controlled trial, with recruitment from primary and secondary care centres in England and Wales and a target sample size of 518 (1:1 allocation; allocation sequence by minimisation programme with built-in random element). The study uses secure web-based allocation concealment. The two treatments will be optimal usual care (control) and optimal usual care plus the ‘Activate Your Heart’ web-based cardiac rehabilitation programme (intervention). Outcome assessment and statistical analysis will be performed blinded; participants will be unblinded. Outcomes will be measured at baseline and at 6 and 12 months’ follow-up. Primary outcome will be the UK version of Seattle Angina Questionnaire (SAQ-UK), physical limitations domain at 12 months’ follow-up. Secondary outcomes will be the remaining two domains of SAQ-UK, dyspnoea, anxiety and depression, health utility, self-efficacy, physical activity and the incremental shuttle walk test. All safety events will be recorded, and serious adverse events assessed to determine whether they are related to the intervention and expected. Concurrent economic evaluation will be cost–utility analysis from health service perspective. An embedded process evaluation will determine the mechanisms and processes that explain the implementation and impacts of the cardiac rehabilitation programme.

Ethics and dissemination
North of Scotland National Health Service Research Ethics Committee approval, reference 21/NS/0115. Participants will provide written informed consent. Results will be disseminated by peer-reviewed publication.

Trial registration number
ISRCTN10054455.

New England Journal of Medicine, Volume 390, Issue 12, Page 1149-1152, March 2024.

Progetto Pascnet contro la nuova emergenza di sanità pubblica